J. Scott Wolchko - 21 Oct 2021 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role
President and CEO, Director
Signature
/s/ Cindy Tahl, as Attorney-in-Fact
Issuer symbol
FATE
Transactions as of
21 Oct 2021
Net transactions value
-$3,399,389
Form type
4
Filing time
25 Oct 2021, 16:04:34 UTC
Previous filing
20 Aug 2021
Next filing
22 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FATE Common Stock Options Exercise $81,900 +30,000 +7.6% $2.73 423,793 21 Oct 2021 Direct F1
transaction FATE Common Stock Sale $911,358 -15,235 -3.6% $59.82* 408,558 21 Oct 2021 Direct F1, F2
transaction FATE Common Stock Sale $895,202 -14,765 -3.6% $60.63* 393,793 21 Oct 2021 Direct F1, F3
transaction FATE Common Stock Options Exercise $27,300 +10,000 +2.5% $2.73 403,793 22 Oct 2021 Direct F1
transaction FATE Common Stock Options Exercise $23,455 +4,846 +1.2% $4.84 408,639 22 Oct 2021 Direct F1
transaction FATE Common Stock Options Exercise $40,916 +15,154 +3.7% $2.70 423,793 22 Oct 2021 Direct F1
transaction FATE Common Stock Sale $1,766,400 -30,000 -7.1% $58.88* 393,793 22 Oct 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FATE Stock Option (Right to Buy) Options Exercise $0 -30,000 -33% $0.000000 60,000 21 Oct 2021 Common Stock 30,000 $2.73 Direct F1, F4
transaction FATE Stock Option (Right to Buy) Options Exercise $0 -10,000 -17% $0.000000 50,000 22 Oct 2021 Common Stock 10,000 $2.73 Direct F1, F4
transaction FATE Stock Option (Right to Buy) Options Exercise $0 -4,846 -100% $0.000000* 0 22 Oct 2021 Common Stock 4,846 $4.84 Direct F1, F4
transaction FATE Stock Option (Right to Buy) Options Exercise $0 -15,154 -13% $0.000000 99,446 22 Oct 2021 Common Stock 15,154 $2.70 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.31 to $60.30 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.31 to $61.26 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 This option is fully vested.